Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is projected to post its Q3 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($1.28) per share and revenue of $44.1730 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same quarter in the previous year, the business posted $2.75 EPS. The firm’s revenue was down 86.4% on a year-over-year basis. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $84.65 on Monday. Arrowhead Pharmaceuticals has a twelve month low of $15.01 and a twelve month high of $95.49. The firm’s fifty day simple moving average is $79.04 and its 200-day simple moving average is $70.70. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of -39.37 and a beta of 1.27. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the transaction, the director owned 52,012 shares in the company, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Maryland State Retirement & Pension System increased its holdings in shares of Arrowhead Pharmaceuticals by 1.8% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company’s stock valued at $1,344,000 after acquiring an additional 365 shares during the period. Corient Private Wealth LLC boosted its stake in Arrowhead Pharmaceuticals by 3.1% during the 4th quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company’s stock worth $1,210,000 after purchasing an additional 551 shares during the period. Empowered Funds LLC grew its position in Arrowhead Pharmaceuticals by 4.5% during the 4th quarter. Empowered Funds LLC now owns 18,018 shares of the biotechnology company’s stock worth $1,196,000 after purchasing an additional 779 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Arrowhead Pharmaceuticals by 10.0% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 9,154 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 829 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $29,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Sanford C. Bernstein boosted their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Piper Sandler reiterated an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. JPMorgan Chase & Co. boosted their price objective on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $96.92.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.